Regulatory Impurity Qualification
Regulatory Impurity Qualification is a formal scientific assessment process within the broader category of process-related impurities that establishes the safety and acceptable levels of impurities in pharmaceutical products through regulatory-approved methodologies, distinguishing it by its requirement for compliance with health authority guidelines and submission in regulatory dossiers.
2
Publications
126
Citations
40
Authors
23
Institutions
Publications per year
2017–2026
1
Parents
2
1–3 of 2
40
2
h-index
2
h-index
1
h-index
1
h-index
1
h-index
1–5 of 40
23
AbbVie (United States)
North Chicago, United States
2 h-index
3 publications
239 citations
Gilead Sciences (United States)
Foster City, United States
2 h-index
3 publications
239 citations
Janssen (United States)
Hopewell, United States
2 h-index
2 publications
126 citations

Vertex Pharmaceuticals (United States)
Boston, United States
2 h-index
2 publications
126 citations
AstraZeneca (United Kingdom)
Cambridge, United Kingdom
1 h-index
1 publications
113 citations
GenVec
Gaithersburg, United States
1 h-index
1 publications
13 citations
Roche (Switzerland)
Basel, Switzerland
1 h-index
2 publications
226 citations
Novartis (Switzerland)
Basel, Switzerland
1 h-index
1 publications
113 citations
1–8 of 23
RTP · 2 publications · 126 citations
2
h-index
1 publications · 12 citations
1–2